Shares of emerging micro-cap Senesco Technologies (NYSE MKT: SNT) have started to wake up after they reported on Monday on the progress of its Phase 1b/2a study for the treatment of multiple myeloma, which is the subject of a poster presented today at the 2012 Annual Meeting of the American Society of Clinical Oncology. The firm is not your typical biotech firm...

Shares of emerging micro-cap Senesco Technologies (NYSE MKT: SNT) have started to wake up after they reported on Monday on the progress of its Phase 1b/2a study for the treatment of multiple myeloma, which is the subject of a poster presented today at the 2012 Annual Meeting of the American Society of Clinical Oncology.

The firm is not your typical biotech firm. They are engaged in the research and development of genetic technologies that improve commercial agriculture-- and treat major medical conditions in humans. While most, frankly, have been skeptical that Senesco's platform technology would work. It appears that there may be something going on scientifically, after all. The company's science is based on the identification and characterization of specific genes that are responsible for plant cell death (senescence) and for programmed cell death in humans (apoptosis).

SNS01-T is a novel approach to cancer therapy that is designed to selectively trigger apoptosis in B-cell cancers such as multiple myeloma, and, mantle cell and diffuse large B-cell lymphomas. Senesco is the sponsor of the Phase 1b/2a study that is actively enrolling patients at Mayo Clinic in Rochester, MN, the University of Arkansas for Medical Sciences in Little Rock, and the Mary Babb Randolph Cancer Center in Morgantown, WV. What caused the excitement is the fact that so far one patient has completed the 6 week dosing schedule. This patient's disease was considered stable, no disease progression, based on key disease markers including monoclonal protein when evaluated at the end of weeks 3 and 6.

Les Browne, Ph.D., President and Chief Executive Officer of Senesco has commented further on the surprising findings and his exclusive in-depth interview with BioMedReports is now available at:

http://www.biomedreports.com/2012060596196/qaa-sns01-t-is-a-new-approach-to-treating-b-cell-cancers-that-can-be-modified-for-all-cancers.html

Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to:

http://biomedreports.com/fdacal.html

News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports

####

About BioMedReports.Com

BioMedReports is a news and research portal covering financial biomedical news and the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. They sell a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release is available at BioMedReports.Com

Media Contacts Only:
Mary Davila,  Assistant Editor, BioMedReports.Com
e-mail: [email protected] Tel: +1 323 472 4480 Fax: +1 888 210 3556

Copyright Thomson Reuters


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: %s via Thomson Reuters ONE


[HUG#1617521]